skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [2];  [2];  [2];  [4];  [5];  [6];  [2];  [2];  [1];  [1]
  1. Department of Medical Oncology, Hospital del Mar, University Autonoma of Barcelona, Barcelona (Spain)
  2. Department of Human Anatomy, Faculty of Medicine, University of Barcelona, Barcelona (Spain)
  3. Department of Otolaryngology, Hospital del Mar, University Autonoma of Barcelona, Barcelona (Spain)
  4. Department of Radiation Oncology, Hospital del Mar, University Autonoma of Barcelona, Barcelona (Spain)
  5. Department of Pathology, Hospital del Mar, University Autonoma of Barcelona, Barcelona (Spain)
  6. Department of Radiology, Hospital del Mar, University Autonoma of Barcelona, Barcelona (Spain)

Purpose: Polymorphisms in DNA repair genes can influence response to radiotherapy. We analyzed single-nucleotide polymorphisms (SNP) in nine DNA repair genes in 108 patients with head-and-neck cancer (HNSCC) who had received radiotherapy only. Methods and Materials: From May 1993 to December 2004, patients with Stage I and II histopathologically confirmed HNSCC underwent radiotherapy. DNA was obtained from paraffin-embedded tissue, and SNP analysis was performed using a real-time polymerase chain reaction allelic discrimination TaqMan assay with minor modifications. Results: Patients were 101 men (93.5%) and 7 (6.5%) women, with a median age of 64 years (range, 40 to 89 years). Of the patients, 76 (70.4%) patients were Stage I and 32 (29.6%) were Stage II. The XPF/ERCC1 SNP at codon 259 and XPG/ERCC5 at codon 46 emerged as significant predictors of progression (p 0.00005 and 0.049, respectively) and survival (p = 0.0089 and 0.0066, respectively). Similarly, when variant alleles of XPF/ERCC1, XPG/ERCC5 and XPA were examined in combination, a greater number of variant alleles was associated with shorter time to progression (p = 0.0003) and survival (p 0.0002). Conclusions: Genetic polymorphisms in XPF/ERCC1, XPG/ERCC5, and XPA may significantly influence response to radiotherapy; large studies are warranted to confirm their role in HNSCC.

OSTI ID:
20850216
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 66, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2006.06.029; PII: S0360-3016(06)01121-7; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English